Medtronic Announced CE (Conformité Européenne) Mark Approval For The MiniMed 780G System With Simplera Sync, Disposable, All-in-one Continuous Glucose Monitor Requiring No Fingersticks Or Overtape
Portfolio Pulse from Benzinga Newsdesk
Medtronic has received CE Mark approval in Europe for its MiniMed 780G system, which includes the Simplera Sync, a disposable continuous glucose monitor that eliminates the need for fingersticks or overtape. This regulatory milestone could enhance Medtronic's product offering in the diabetes care market in Europe.
January 08, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medtronic's MiniMed 780G system with Simplera Sync has been granted CE Mark approval, potentially boosting its diabetes care portfolio in Europe and possibly increasing market share.
The CE Mark approval is a significant regulatory achievement that allows Medtronic to market the MiniMed 780G system in the European market. This could lead to increased sales and market penetration in the short term, as the product addresses a key patient convenience factor by eliminating the need for fingersticks. The news is directly related to Medtronic and is likely to be viewed positively by investors, hence the positive score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100